Abstract
Vaccination-based exposure to spike protein derived from early SARS-CoV-2 sequences is the key public health strategy against COVID-19. Successive waves of SARS-CoV-2 infections have been characterised by the evolution of highly mutated variants that are more transmissible and that partially evade the adaptive immune response. Omicron is the fifth of these “Variants of Concern” (VOC) and is characterised by a step change in transmission capability, suggesting significant antigenic and biological change. It is characterised by 45 amino acid substitutions, including 30 changes in the spike protein relative to one of the earliest sequences, Wuhan-Hu-1, of which 15 occur in the receptor- binding domain, an area strongly associated with humoral immune evasion. In this study, we demonstrate both markedly decreased neutralisation in serology assays and real-world vaccine effectiveness in recipients of two doses of vaccine, with efficacy partially recovered by a third mRNA booster dose. We also show that immunity from natural infection (without vaccination) is more protective than two doses of vaccine but inferior to three doses. Finally, we demonstrate fundamental changes in the Omicron entry process in vitro, towards TMPRSS2-independent fusion, representing a major shift in the replication properties of SARS-CoV-2. Overall, these findings underlie rapid global transmission and may alter the clinical severity of disease associated with the Omicron variant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The EVADE study is supported by HDR-UK (E.C.T). COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute (G.M., R.M.B., D.L.R., E.C.T.). The COVID-19 DeplOyed VaccinE (DOVE) study is funded by the Medical Research Council core award (MCUU1201412) and COG-UK. We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1) funded by the UKRI (M.P.,E.C.T.). A.F., J.H., R.O and D.L.R acknowledge the MRC (MC_UU_12014/12) and DLR the Wellcome Trust (220977/Z/20/Z). W.T.H. is funded by the MRC (MR/R024758/1 and MR/W005611/1). N.L. and B.J.W. were funded by the Biotechnology and Biological Sciences Research Council (BBSRC, BB/R004250/1), G.T. was funded by the Department of Health and Social Care (DHSC, BB/R019843/1). J.G. is supported by a Sir Henry Dale Fellowship from the Wellcome Trust and Royal Society (107653/Z/15/A) and by the Medical Research Council (MC_UU_12014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The North West Central Liverpool Research Ethics Committee/IRB gave ethical approval for the DOVE study (21/NW/0073). Informed written consent was obtained for all participants. In addition, the NHS GG&C SafeHaven gave derogated ethical approval for the use of anonymised population data (GSH/21/IM/001). NHS Caldicott approval was also obtained for the use of anonymised clinical data. Lothian biorepository ethical approval was given for the isolation of virus from clinical samples (reference 10/S1402/33).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵*** Full list of consortium names and affiliations are listed in the appendix
Data Availability
All sequence data are published via GISAID. All data produced in the present study are available upon reasonable request to the authors other than identifying clinical information.
